Biblio

Author Title [ Type

] Year

Filters: Author is Schwind, Sebastian [Clear All Filters]

Journal Article

Grimm J, Jentzsch M, Bill M, Backhaus D, Brauer D, Küpper J, Schulz J, Franke G-N, Vucinic V, Niederwieser D, et al. Clinical Implications of SRSF2 Mutations in AML Patients undergoing Allogeneic Stem Cell Transplantation. Am J Hematol. 2021.

Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HKathrin, Schwind S, Jentzsch M, Cross M, Kahl C, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023.

Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LKatharina, Backhaus D, Brauer D, Goldmann K, Franke G-N, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2022.

Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke G-N, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. Blood Adv. 2022.

Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia. 2023.

Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke G-N, Herling M, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170.

Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TPham, Merz M, Franke G-N, et al. Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?. Hemasphere. 2024;8(3):e55.

Teipel R, Rieprecht S, Trautmann-Grill K, Röllig C, Klötzer C, Zimmer K, Rathaj G, Bach E, Brückner M, Heyn S, et al. Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma. Transfusion. 2023.

Vucinic V, Jentzsch M, Leiblein S, Bach E, Remane Y, Schulze-Forster K, Cross M, Pönisch W, Schwind S, Franke G-N, et al. Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39). Transfusion. 2021.